Compare Biogen Inc (BIIB) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs QUALCOMM, Inc. — how do they compare? Biogen Inc trades at $191.89 (market cap $28.34B), while QUALCOMM, Inc. trades at $179.28 (market cap $187.72B). The key difference: QUALCOMM, Inc. is far larger — about 6.6× Biogen Inc's market cap, and QUALCOMM, Inc. pays a 2.07% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | QCOM | |
|---|---|---|
Market Cap | $28.34B | $187.72B |
Sector | Health | Technology |
52-Week High | $216.63 | $251.10 |
52-Week Low | $122.68 | $124.07 |
Enterprise Value | $30.62B | $193.19B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Qualcomm (QCOM) trades at $178.08, down 5.86% over 24 hours, with a bearish technical signal and mixed sentiment. The stock shows strong profitability with a 22.31% net income margin and consistent earnings beats in recent quarters. Recent news highlights its AI and data center diversification amid smartphone market challenges, with CEO Cristiano Amon projecting 'multiple billions' in data center revenue ahead (MarketBeat, June 2, 2026).
The outlook balances growth in AI and automotive against near-term margin pressures and competition. Analysts see upside to a $222.53 consensus target, but risks include Nvidia's entry into PC chips and soft smartphone demand. The stock offers value at a P/E of 19.78, with dividends providing income support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
